AppLovin Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AppLovin Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.48B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.22B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.84B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $2.82B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.79B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.45B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $994.10M | Mar 11, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.48B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.22B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.84B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $2.82B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.79B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.45B | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $994.10M | Mar 11, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.33B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.58B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $356.71M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($192.75M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $35.45M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($125.19M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $119.04M | Mar 11, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.15B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.91B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $772.41M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($47.79M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $150.02M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($62.04M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $194.37M | Mar 11, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.51M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $374.71M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $333.78M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $507.61M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $366.40M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $180.65M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $44.97M | Mar 11, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.97B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.10B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.06B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $412.77M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $361.85M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $222.88M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $198.46M | Mar 11, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.78M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $4.25M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $662.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.39M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $3.24M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $3.36M | Mar 11, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.26B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $5.87B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $5.36B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.85B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $6.16B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.15B | Mar 11, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.12B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.78B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $4.10B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.95B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $4.03B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.31B | Mar 11, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.13B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.09B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.26B | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $1.90B | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $2.14B | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | ($158.55M) | Feb 26, 2024 |
| FY2022 | Dec 31, 2019 | ($256.57M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2018 | ($378.36M) | Mar 11, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.46B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.50B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.82B | Feb 27, 2025 |
| FY2023 | Jun 30, 2022 | $1.82B | Feb 26, 2024 |
| FY2022 | May 31, 2022 | $1.82B | Feb 28, 2023 |
| FY2023 | Dec 31, 2021 | $966.43M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $249.77M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $137.12M | Mar 11, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.74B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $599.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($812.99M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.17B) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($976.95M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.01B) | Mar 11, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.49B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $697.03M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $502.15M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.08B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.52B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $317.24M | Mar 11, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.51B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.51B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.12B | Feb 27, 2025 |
| FY2022 | Dec 31, 2022 | $3.21B | Feb 28, 2023 |
| FY2021 | Dec 31, 2021 | $3.23B | Mar 11, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 11, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 11, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 338.31M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 340.04M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 339.89M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 373.87M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 375.09M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 226.36M | Mar 11, 2022 |